Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05339711
Other study ID # RCS09042022
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2021
Est. completion date September 1, 2021

Study information

Verified date November 2023
Source Karadeniz Technical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The research was carried out as a randomized controlled trial to examine the physiological and psychological effects of robotic cat and Betta fish therapies in hemodialysis patients.


Description:

Along with the benefit of hemodialysis treatment, patients develop physical and psychosocial problems and symptoms associated with hemodialysis. Undesirable symptoms experienced by patients undergoing hemodialysis include hypotension/hypertension, respiratory distress, headache, back-chest pain, muscle cramps, nausea-vomiting, fatigue, fever, constipation, diarrhea, itching. In addition to negative feelings such as anger, anxiety, unhappiness and fear associated with hemodialysis, patients often experience adjustment disorder, anxiety, depression and sleep disorders, and may experience social isolation and loneliness with the fear of being a burden to their friends or family members. The physical symptoms that patients receiving hemodialysis treatment have to cope with and psychological symptoms such as unhappiness and loneliness make it difficult to adapt to their disease and contribute to an increase in mortality. Today, "pet therapy" is used for treatment in many hospitals, psychiatry clinics, nursing homes and rehabilitation centers. Pet therapy is an application in the Nursing Interventions Classification. In studies with different animals on different populations in health services, hospitals, psychiatry clinics, nursing homes and rehabilitation centers, pet therapy; It is stated that it has physiological and psychological benefits such as decrease in psychiatric signs and symptoms, increase in cardiovascular system functionality, increase in socialization skills and individual self-management. It is reported that the physiological and psychological benefits of pet therapy applications have been proven in many of the studies using many animals (such as birds, dogs, cats, fish) and robot simulations. It has been reported that robotic pet therapy reduces depression, agitated behaviors, pain, stress hormone levels and loneliness, increases heart rate, happiness, and quality of life. Again, it is stated that even a simple movement of live animals reduces loneliness, anxiety, depression and social isolation in humans. It has been determined that an unpublished experimental doctoral thesis study, of which a poster statement can be reached, was conducted abroad on the effect of "the effect of pet therapy with live dogs on depression" in patients with CRF. Again, one pilot study and one pre-test-post-test study were found in which the effect of pet therapy on happiness with a live dog was examined. In Turkey, no study was found with pet therapy in patients undergoing CRF and hemodialysis. However, there is limited information in the literature about the benefits of human-fish interactions related to pet therapy. It has been reported that ornamental betta fish increase individual self-management, and reduce anxiety and stress. In a systematic review, it was reported that various fish species reduced anxiety, physiological stress, anxiety and pain, provided relaxation, improved food intake, had positive benefits on mood and body weight (weight gain), but no information was found about loneliness. About the subject, only pet therapy with live dogs was used in hemodialysis patients, and no experimental study was found. In addition, it was determined that there was no information about the effect of Betta fish therapy on loneliness and that happiness, dialysis symptoms, compliance with ESRD, and body mass index (BMI) were not examined before in patients undergoing hemodialysis. The fact that the mentioned parameters were not examined indicates that there is a lack of evaluation of robotic cat or Betta fish therapies. In line with this information, the aim of this study was to examine the positive physiological (dialysis symptoms, BMI) and psychological (dialysis symptoms, happiness, loneliness, adaptation to ESRD) effects of robotic cat and Betta fish therapies in patients undergoing hemodialysis.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date September 1, 2021
Est. primary completion date July 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Being =18 years old, - Accepting to participate in the research, - Being literate, - Being able to communicate verbally, - Receiving outpatient hemodialysis treatment three times a week in the same institution, - Absence of any impairment in mental and cognitive functions, - Weight and height measurements can be made while standing, - Being on hemodialysis treatment for at least three months (33), - Being able to perform self-care activities independently, - Not having allergies for patients in the robot cat group, - Desiring to spend time with the robotic cat "Silver" during hemodialysis by the patients in the robot cat group, - Wanting to nutrition and care fish at home by patients in the betta fish group. Exclusion Criteria: - Refusal to participate in the research, - Being on peritoneal dialysis, - Being diagnosed with a psychiatric disorder diagnosed by a psychiatrist, - Unstable general condition (hemodynamically) (heart rate <60 beats/min, systolic blood pressure <100 mm/Hg or diastolic blood pressure <60 mm/Hg), - Patients with chronic obstructive pulmonary disease (COPD) (except Mild COPD Stage 1) and advanced heart failure were identified (34, 35).

Study Design


Intervention

Other:
Robotic Pet Therapy/Robot Cat Group
In this study, the patients interacted with the robot cat "Silver" for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher.
Pet Therapy/Betta Fish Group
In this study, two fish and the necessary materials (aquarium, fish food, plastic plant, aquarium stone, etc.) were given to the patients by the researcher to keep pets for eight weeks.

Locations

Country Name City State
Turkey Karadeniz Tecnical University Trabzon

Sponsors (1)

Lead Sponsor Collaborator
Karadeniz Technical University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body mass Index Monitoring This form includes BMI, an anthropometric measurement. To obtain the Body Mass Index, the patient's body weight (kg) was divided by the square of the height (m) (BMI=kg/m2).
Before the research, 5 measurements were made, twice in the 1st month and 2nd month when pet therapy was applied, and twice in the two-month follow-up after the pet therapy application was terminated.
16 week
Primary De Jong Gierveld Loneliness Scale The scale was first developed by De Jong Gierveld and Kamphuis in 1985. The Turkish adaptation of the scale with factor loadings between 0.64-0.86 was carried out by Çavdar, Bagci, Chorbaci, Saritas and Tasdelen in 2015. Social loneliness and emotional loneliness two sub-scale in size 11 items in Scale. It is a four-point likert (4=Very convenient, 3=Convenient, 2=Not convenient, 1=Not convenient at all) type scale. Since the items in the social loneliness dimension contain positive statements, these items are reverse items. As the score obtained from the scale increases, the levels of loneliness increase.
Before the research, 5 measurements were made, twice in the 1st month and 2nd month when pet therapy was applied, and twice in the two-month follow-up after the pet therapy application was terminated.
16 week
Primary Subjective Happiness Scale (SHS) Developed by Lyubomirsky and Lepper, SHD is a seven-point Likert type, self-report style. The scale consists of four items; Since the fourth item contains a negative statement, this item is the reverse item. The lowest score taken from the scale is four, the highest score is 28, and as the individual's scale score increases, the level of happiness increases.
Before the research, 5 measurements were made, twice in the 1st month and 2nd month when pet therapy was applied, and twice in the two-month follow-up after the pet therapy application was terminated.
16 week
Primary End Stage Renal Disease (ESRD)-Adherence Questionnaire This scale was developed by Kim, Evangelista, Phillips, Pavlish, and Kopple. The ESRD-Adaptation Scale consists of four compliance behaviors subscales: participation in treatment (1st, 3rd and 5th items), medicine use (6th item), fluid restriction (8th item), and dietary restriction (9th item). Items 2, 5 and 7 of the items do not have a point value. The range of scores that can be obtained from the scale is between 0-1200, and as the score increases, the compliance of the patients with the treatment also increases.
Before the research, 5 measurements were made, twice in the 1st month and 2nd month when pet therapy was applied, and twice in the two-month follow-up after the pet therapy application was terminated.
16 week
Primary Dialysis Symptom Index (DSI) Weisbord et al. has a total of 30 items in which both emotional and physical symptoms of dialysis patients and the severity of these symptoms are evaluated. After the patients answered yes-no to the questions regarding the symptoms they experienced within a week, their symptoms with a yes answer are re-evaluated in a five-point Likert type ("5 points: A lot", "4 points: Very little", "3 points: Sometimes", "2 points: A little", "1 point: Not at all"). The total score to be obtained from the scale ranges from 0 to 150.
Before the research, 5 measurements were made, twice in the 1st month and 2nd month when pet therapy was applied, and twice in the two-month follow-up after the pet therapy application was terminated.
16 week
See also
  Status Clinical Trial Phase
Recruiting NCT04892745 - Impact of Hemodialysis on Cutaneo-muscular Electrical Impedance
Not yet recruiting NCT04925674 - Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis. Phase 1
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03365635 - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Phase 4
Withdrawn NCT02904343 - Evaluation of Domestic Hemodialysis Machine: A Multi-center Clinical Study N/A
Withdrawn NCT01855334 - L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD Phase 4
Completed NCT01700465 - Estimating and Predicting Hemodynamic Changes During Hemodialysis N/A
Recruiting NCT01195519 - The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis N/A
Completed NCT00737672 - GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis Phase 3
Completed NCT00527774 - Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients N/A
Completed NCT00942253 - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS) Phase 2
Completed NCT00224081 - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) Phase 4
Completed NCT00850252 - Use of a Lifeline Graft in the A-V Shunt Model Phase 1/Phase 2
Completed NCT00776750 - Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients Phase 4
Recruiting NCT06351007 - Educational Program on Dietary Adherence and Nutritional Knowledge in Chronic Kidney Disease Patients (EPAK) N/A
Withdrawn NCT03664141 - Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study) Phase 3
Completed NCT03909698 - Antibiotic Dosing in Patients on Intermittent Hemodialysis
Recruiting NCT03311321 - Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients N/A
Recruiting NCT06098924 - HD Patients' Depression and Happiness
Recruiting NCT03419923 - Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage N/A